There is one clinical trial.
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. This study aims to investigate the safety and efficacy of intravenous infusion of natural killer cells patients with COVID-19.
Description: Assessment of Overall survival at 30 days post interventionMeasure: Overall survival Time: 30 days
Description: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein (mg/dL)Measure: Changes on inflammatory C-reactive protein Time: 60 days
Description: days of the patients in hospitalMeasure: Hospital stay Time: 60 days
Description: Evaluation of functional respiratory changes: PaO2 / FiO2 ratioMeasure: Oxygenation index (PaO2/FiO2) Time: 60 days
Description: Improvement in Liao's score (2020)Measure: Improvement in Liao's score (2020) Time: 60 days
Description: Computed tomography Chest assesment will be done to assess improvement in radiological findings of COVID-19Measure: Radiological improvement Time: 60 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports